Calpain-dependent proteolysis of NF2 protein: Involvement in schwannomas and meningiomas

Neuropathology

Volumn 20, Issue 3, 2000, Pages 153-160

  Kimura, Yoriyoshi ^a   Saya, Hideyuki ^b   Nakao, Mitsuyoshi ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Calpain; Meningioma; Merlin; Neurofibromatosis type 2 (NF2); Schwannoma

Indexed keywords

CALPAIN; CALPASTATIN; DILTIAZEM; MERLIN; NIFEDIPINE; VERAPAMIL;

CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; ENZYME ACTIVITY; GENE MUTATION; HUMAN; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TREATMENT INDICATION;

CALPAIN; GENES, NEUROFIBROMATOSIS 2; HUMANS; MEMBRANE PROTEINS; MENINGIOMA; MUTATION; NEURILEMMOMA; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PEPTIDE HYDROLASES;

EID: 0034426280     PISSN: 09196544     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1789.2000.00326.x     Document Type: Review

References (58)

1. Neurofibromatosis type 2: Loss of merlin's protective spell
2. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis)
3. Neurofibromatosis type 2: A new mechanism of tumor suppression
4. Central neurofibromatosis with bilateral acoustic neurinoma
5. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2
6. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor
7. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas
8. Ocular abnormalities in neurofibromatosis 2
9. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2
10. Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis
11. Neurofibromatosis 2: Clinical and DNA linkage studies of a large kindred
12. ERM (ezrin/radixin/moesin) family: From cytoskeleton to signal transduction
13. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker
14. Neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin
15. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation
16. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors
17. The merlin tumor suppressor localizes preferentially in membrane ruffles
18. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells
19. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity
20. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which miss exons in the ERM-homology domain
21. Type of mutations in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease
22. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
23. Molecular characterization of chromosome 22 deletions in schwannomas
24. The neurofibromatosis type 2 gene is inactivated in schwannomas
25. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
26. Alternative splicing of the NF2 gene and its mutation: Analysis of breast and colorectal cancers
27. Mutations in transcripts isoforms of the neurofibromatosis type 2 gene in multiple human tumour types
28. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas
29. Mutational analysis of patients with neurofibromatosis 2
30. Detection of cellular proteins that interact with the NF2 tumor suppressor gene product
31. Universal absence of merlin, but not other ERM family members, in schwannomas
32. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas
33. Reduced expression of schwannomin/merlin in human sporadic meningiomas
34. Calpain: New perspectives in molecular diversity and physiological-pathological involvement
35. Calpain: Novel family members, activation, and physiologic function
36. Structure and physiological function of calpains
37. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine
38. Structure and functions of the 20S and 26S proteasomes
39. Electroblotting of proteins to Teflon tape and membranes for N- and C- terminal sequence analysis
40. Brain fodrin: Substrate for calpain I, an endogenous calcium-activated protease
41. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments
42. Involvement of calpain in integrin-mediated signal transduction
43. Proteolytic cleavage of alpha-actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody
44. Expression in Escherichia coli, phosphorylation with cAMP-dependent protein kinase and proteolysis by calpain of a 71-kDa domain of human endothelial actin binding protein
45. Proteolysis of platelet cortactin by calpain
46. Phosphorylation of connexin-32 by protein kinase C prevents its proteolysis by μ-calpain and m-calpain
47. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain
48. Phosphorylation modulates calpain-mediated proteolysis and calmodulin binding of the 200-kDa and 160-kDa neurofilament proteins
49. Proteolysis of tubulin and microtubule-associated proteins 1 and 2 by calpain I and II: Difference in sensitivity of assembled and disassembled microtubules
50. Autolytic transition of μ-calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms
51. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
52. Kip1 protein: Prognostic implications in primary breast cancer
53. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
54. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas
55. Treatment of acoustic neuromas
56. Emerging therapeutic targets in schwannomas and meningiomas: The neurofibromatosis type 2 protein
57. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists
58. Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists. Part II: Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements